Nacionalinis vezio institutas — Clinical Trial Site

22 Registered trials

2 Currently recruiting

Organisation

Nacionalinis vezio institutas

Location

Vilnius, Lithuania

Identifier

ORG-100042993

Address

Santariskiu G. 1, Vilniaus M. Sav., 08660, Lithuania

Departments

#2601: Conservative Tumour Therapy
#93136001:Conservative Tumour Therapy
#98336001
Chemotherapy Day Inpatient Unit
Chemotherapy Department with Day Care Subdepartment
Chemotherapy department with day inpatient
Conservative Tumour Therapy
Department of Chemotherapy
department of oncology
Department of Thoracic surgery and Oncology
Medical Oncology
Medical Oncology Department
N/A
Nacionalinis Vėžio Institutas
None
Oncology department
Oncology-Urology
Onkourologijos skyrius
Urology

Clinical trials at this site (22)

Search interface

A Phase 2, Open-Label, Single-Arm, Multicentre Study Investigating the Pharmacokinetics, Pharmacodynamics, Efficacy and Safety of Teverelix … Pending

2023-509255-14-01 Advanced prostate cancer 4
A study to compare effects and safety of CT-P51 and Keytruda in patients with previously untreated metastatic lung cancer Recruiting

2024-514048-98-00 Previously Untreated Metastatic Non-Squamous Non-Small 5 2025-01-30
A phase 3 study to evaluate petosemtamab vs. investigator's choice in previously treated metastatic / recurrent head and neck cancer. Recruiting

2023-510322-32-00 patients with incurable, metastatic/recurrent head and 5 2025-01-27
A study to continue providing GME751 (a new medicine that is similar to pembrolizumab) to participants who are eligible for pembrolizumab tr… Ended

2024-513160-25-00 Melanoma and Non-small-cell lung cancer 5 2024-10-30
A Study to Evaluate ABP 206 Compared with OPDIVO® (Nivolumab) in Subjects with Unresectable or Metastatic Melanoma Ended

2023-503288-40-00 Unresectable or Metastatic Melanoma 5 2024-01-26
A phase 3 clinical trial of a new combination treatment, domvanalimab and zimberelimab, plus chemotherapy, for people with an upper gastroin… Ended

2023-507522-16-00 Metastatic Esophageal or Gastric Cancer 5 2023-05-22
An open study for participants who have been on darolutamide treatment in any other Bayer study Ended

2022-502084-38-00 Cancer 5 2020-10-16
Investigation of Radium-223 dichloride (Xofigo), a treatment that gives off radiation that helps kill cancer cells, compared to a treatment … Ended

2023-505830-89-00 metastatic castrate resistant prostate cancer (mCRPC) 6 2020-08-05
Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell… Ended

2023-503591-25-00 Non-small cell lung cancer 5 2020-06-09
A randomized phase II study comparing atezolizumab after concurrent chemoradiotherapy with chemoradiotherapy alone in limited disease small-… Ended

2024-515755-37-00 Limited disease small-cell lung cancer 4 2018-07-31
Chemo +/- Pembrolizumab (MK-3475) as Perioperative Therapy for Stage II, IIIA-Resectable IIIB (N2) NSCLC Ended

2023-504820-24-00 Neoadjuvant/Adjuvant treatment for participants with Re 5 2018-03-21
Integrated PK/efficacy, safety, and immunogenicity study to demonstrate similarity of JPB898, a proposed biosimilar to nivolumab, to Opdivo®… Ended

2023-507865-24-00 Advanced (unresectable/metastatic) melanoma 5 2025-03-28
A Pharmacokinetics (PK) study to compare GME751 (proposed pembrolizumab biosimilar) and United States (US)-licensed and European Union (EU)-… Ended

2023-506881-30-00 Melanoma 3 2024-05-15
Phase 2/3 Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer Ended

2022-502196-31-00 Advanced or Recurrent Endometrial Cancer 10 2023-08-21
A Study Evaluating Pharmacokinetic Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected Stage III and Stage IV … Ended

2022-502620-49-00 Resected Melanoma Stage III or Stage IV 2 2023-08-01
Study of Nemvaleukin Alfa in Combination with Pembrolizumab Versus Investigator's Choice Chemotherapy in Patients with Platinum-Resistant Ep… Ended

2024-513230-38-00 Platinum-Resistant Epithelial Ovarian, Fallopian Tube, 5 2022-12-15
An open-label, phase I multicenter, clinical trial of NECVAX-NEO1 in addition to anti-PD-1 or anti-PD-L1 monoclonal antibody checkpoint inhi… Ended

2024-513716-95-00 Non-Small Cell Lung Cancer, cutaneous melanoma, urothel 1 2022-05-16
Study Comparing Bemarituzumab plus Chemotherapy with Placebo and Chemotherapy in Previously Untreated Advanced Gastric or Gastroesophageal J… Ended

2023-505457-40-00 Previously Untreated Advanced Gastric or Gastroesophage 5 2022-02-02
A trial to learn how well darolutamide plus androgen deprivation therapy (ADT) works in comparison to placebo plus ADT in men with prostate … Ended

2022-502244-12-00 Metastatic hormone-sensitive prostate cancer (mHSPC) 5 2021-02-22
A study to assess how radium-223 moves through the patients with prostate cancer receiving radium-223 dichloride treatment. Ended

2023-506435-15-00 Prostate cancer 3 2020-08-25
First line treatment with osimertinib in non-small cell lung cancer, coupled with studies on biological samples. Ended

2024-513881-20-00 EGFR-mutated non-small cell lung cancer 4 2018-11-19
Perioperative treatment of locally advanced resectable gastric or GEJ adenocarcinoma Ended

2023-509595-42-00 Gastric and gastroesophageal junction (GEJ) adenocarcin 5 2017-10-31